3 Pharma Exporter, Boron Chemical and Basmati Rice Stocks With a Strong Future Roadmap: Lincoln Pharmaceuticals, Indo Borax & Chemicals and LT Foods

Pharma exporter, boron chemical and basmati rice stocks give investors exposure to medicines, industrial chemicals and food staples sold at home and abroad. Volumes, pricing and input costs decide how much of that demand turns into profit.

This list covers three pharma exporter, boron chemical and basmati rice stocks: Lincoln Pharmaceuticals for formulations sold in India and emerging export markets, Indo Borax & Chemicals for boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture and LT Foods for basmati rice and packaged foods sold under brands such as Daawat. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Pharma Exporter, Boron Chemical and Basmati Rice Stocks?

Pharma exporter, boron chemical and basmati rice stocks are shares of companies that make medicines, chemicals or packaged food. Results depend on volumes, pricing and input costs, so margins and cash flow separate the stronger names.

Pharma Exporter, Boron Chemical and Basmati Rice Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three pharma exporter, boron chemical and basmati rice stocks as of the 14 Oct 2026 close.

Among healthcare and chemicals stocks, all three trade at a discount to their industry P/E multiples.

Why Do Pharma Exporter, Boron Chemical and Basmati Rice Stocks Have a Strong Roadmap in India?

Pharma exporter, boron chemical and basmati rice stocks have a strong roadmap in India because export demand for medicines, glass and ceramic output and global appetite for basmati keep adding volumes for these firms. Three drivers stand out.

• Pharma exports: Emerging markets add demand for formulations.
• Industrial use: Glass, ceramics and farms use boron chemicals.
• Rice exports: Global buyers prefer basmati varieties.

Lincoln Pharmaceuticals: Formulations for India and Export Markets Build the Next Leg

Lincoln Pharma's roadmap rests on formulations sold in India and emerging export markets, with a broad product list supporting revenue.

Revenue grew from Rs 482.12 crore in FY22 to Rs 704.48 crore in FY26, a 46.1% rise, and FY26 revenue was 9.1% higher than FY25. FY26 net profit rose 6.7% to Rs 87.89 crore. Over four years, net profit rose from Rs 69.36 crore in FY22 to Rs 87.89 crore. In Q1 FY27, revenue grew 19.0% to Rs 201.54 crore, and net profit rose 30.9% to Rs 36.23 crore.

Debt to equity is 0.01 and return on equity is 11.60%. The dividend yield is 0.32%. At a P/E of 11.64 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The P/E of 11.64 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Indo Borax & Chemicals: Boron Chemicals Anchor the Roadmap

Indo Borax's roadmap rests on boron-based chemicals such as boric acid and borax used in glass, ceramics and agriculture, with wide industrial usage supporting volumes.

Revenue grew from Rs 178.93 crore in FY22 to Rs 230.89 crore in FY26, a 29.0% rise, and FY26 revenue was 21.0% higher than FY25. FY26 net profit rose 18.3% to Rs 50.27 crore. Over four years, net profit rose from Rs 36.37 crore in FY22 to Rs 50.27 crore. In Q1 FY27, revenue grew 28.9% to Rs 72.92 crore, and net profit rose 59.3% to Rs 16.25 crore. Operating margin was 27.28% in FY26 and 31.78% in Q1 FY27 against 28.43% a year earlier.

Debt to equity is 0.00 and return on equity is 11.09%. FY26 operating cash flow was Rs 87.15 crore against capital expenditure of Rs 0.29 crore. Indo Borax paid a dividend of Rs 1 per share for FY26, a yield of 0.21%. At a P/E of 27.49 against an industry P/E of 36.60, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 31.78% against 27.28% for FY26, so margin stability is the figure to follow as volumes grow.

LT Foods: Basmati and Packaged Foods Anchor the Roadmap

LT Foods' roadmap rests on basmati rice and packaged foods sold under brands such as Daawat, with exports and branded sales supporting revenue.

Revenue grew from Rs 5,450.58 crore in FY22 to Rs 11,023.06 crore in FY26, a 102.2% rise, and FY26 revenue was 25.7% higher than FY25. FY26 net profit rose 2.2% to Rs 625.38 crore. Over four years, net profit rose from Rs 309.20 crore in FY22 to Rs 625.38 crore. In Q1 FY27, revenue grew 26.4% to Rs 3,161.29 crore, and net profit rose 8.9% to Rs 183.45 crore. Operating margin was 11.35% in FY26.

Debt to equity is 0.36 and return on equity is 13.83%. FY26 operating cash flow was Rs 910.50 crore against capital expenditure of Rs 359.62 crore. LT Foods paid a dividend of Rs 3 per share for FY26, a yield of 0.74%. At a P/E of 21.98 against an industry P/E of 34.85, the stock trades below its industry multiple.

What to watch: The P/E of 21.98 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters' growth is the figure to follow.

Best Pharma Exporter, Boron Chemical and Basmati Rice Stocks in India: Lincoln Pharma vs Indo Borax vs LT Foods on Key Financials

Among the best pharma exporter, boron chemical and basmati rice stocks in India, Lincoln Pharma leads on the lowest P/E; Indo Borax leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; LT Foods leads on FY26 revenue growth and return on equity. The table puts the numbers side by side.

Healthcare, chemicals and food earnings follow volumes, pricing and input costs, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Pharma Exporter, Boron Chemical and Basmati Rice Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen pharma exporter, boron chemical and basmati rice stocks and shortlist pharma exporter, boron chemical and basmati rice stocks to buy.

1. Compare each stock's P/E with its industry P/E, which differs by company here.
2. Check operating margin, debt and cash flow together.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these pharma exporter, boron chemical and basmati rice stocks

Risks to Consider Before Investing in Pharma Exporter, Boron Chemical and Basmati Rice Stocks

• Input costs: Changes in raw material prices can affect margins.
• Seasonal demand: Weather and crop cycles can shift sales between quarters.
• Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.

Download the Univest iOS App or Univest Android App to track Lincoln Pharma, Indo Borax and LT Foods live.

Final Take: Which Stock Has the Strongest Roadmap?

These three healthcare and chemicals stocks cover pharma formulations, boron chemicals and basmati rice. Lincoln Pharma leads on the lowest P/E; Indo Borax leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; LT Foods leads on FY26 revenue growth and return on equity.

Across pharma exporter, boron chemical and basmati rice stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the pharma exporter, boron chemical and basmati rice stocks to buy discussed here.

FAQs on Pharma Exporter, Boron Chemical and Basmati Rice Stocks

Which are the best pharma exporter, boron chemical and basmati rice stocks in India with a strong roadmap?

Ans. Lincoln Pharmaceuticals, Indo Borax & Chemicals and LT Foods stand out for their roadmaps in pharma formulations, boron chemicals and basmati rice. FY26 revenue growth was 9.1% at Lincoln Pharma, 21.0% at Indo Borax and 25.7% at LT Foods, and return on equity ranges from 11.09% to 13.83%.

Is Lincoln Pharmaceuticals a good stock to buy now?

Ans. Lincoln Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 11.60% and a P/E of 11.64 against an industry P/E of 37.59. Valuation, input costs and seasonal demand move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Lincoln Pharma, Indo Borax and LT Foods?

Ans. The P/E ratio is 11.64 for Lincoln Pharma (industry 37.59), 27.49 for Indo Borax (industry 36.60) and 21.98 for LT Foods (industry 34.85). All of them trade below the industry multiple.

Which of these pharma exporter, boron chemical and basmati rice stocks has the highest return on equity?

Ans. LT Foods has the highest return on equity at 13.83%, followed by Lincoln Pharmaceuticals at 11.60% and Indo Borax & Chemicals at 11.09%.

What are the risks of investing in pharma exporter, boron chemical and basmati rice stocks?

Ans. The main risks are input costs, seasonal demand and quarterly trends. Changes in raw material prices can affect margins.

How did Lincoln Pharma, Indo Borax and LT Foods perform in Q1 FY27?

Ans. Lincoln Pharmaceuticals reported revenue of Rs 201.54 crore, up 19.0% year on year, and net profit rose 30.9% to Rs 36.23 crore. Indo Borax & Chemicals reported revenue of Rs 72.92 crore, up 28.9% year on year, and net profit rose 59.3% to Rs 16.25 crore. LT Foods reported revenue of Rs 3,161.29 crore, up 26.4% year on year, and net profit rose 8.9% to Rs 183.45 crore.

Do pharma exporter, boron chemical and basmati rice stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.32% for Lincoln Pharma, 0.21% for Indo Borax and 0.74% for LT Foods, based on dividends declared for FY26.

How can I invest in pharma exporter, boron chemical and basmati rice stocks in India?

Ans. You can buy pharma exporter, boron chemical and basmati rice stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.